[citation needed] Cucurbitacin possesses dose-dependent anti-inflammatory activity related to its inhibition of nitric oxide (an RNS) production in macrophages without affecting the viability of these cells.

[citation needed] As cucurbitacin E doesn't affect normal human liver cells, it may have therapeutic potential and effective treatment for a variety of inflammation mediated diseases.

Its antioxidant and free-radical scavenging properties were measured by the ability of cucurbitacin glycoside combination (CGC), a combination of cucurbitacin B and E glycosides, to reduce ABTS cation to its original form and also the capacity to inhibit MDA formation originated in the oxidation of linoleic acid.

Anti-angiogenesis property of cucurbitacin E was demonstrated in vitro but also in vivo in a chick embryo chorioallantoic membrane and in a mouse corneal angiogenesis model.

[7] In vitro, cucurbitacin E protects hepatocytes from CCl4 (carbon tetrachloride), by reducing GPT, GOT, ALP, TP and TBIL serums.